BioNTech’s Bold Leap: From Pandemic Profits to Pioneering Cancer Treatments
BioNTech is transitioning from COVID-19 vaccine success to focus on mRNA-based cancer therapies. Despite a decline in revenue and profits, BioNTech's financial performance in 2024 exceeded market expectations, with earnings…